Absolutely, DrYonky. A Big Pharma would just love to get hold of the OmniCar platform just for themselves! Greedy b@st@rds... and just as likely to shelve it if it means making more money with their less effective CarT drugs and preventing a rival from acquiring it. BUT I just don't see that happening simply because the binders have been licensed to Prescient. I reckon that Penn and Oxford University would want to see their breakthrough technology used to save lives (which isn't always Big Pharma's prioity)! So collaborations as opposed to an outright sale is whats on the cards here.
